中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

47 records (took 0.06 seconds)

    Nerve Growth Factor Conjugates and Uses Thereof
    13.
    发明申请
    Nerve Growth Factor Conjugates and Uses Thereof 审中-公开
    神经生长因子共轭体及其用途

    公开(公告)号：US20110212122A1

    公开(公告)日：2011-09-01

    申请号：US12809261

    申请日：2008-12-22

    Applicant: Martin Bachmann ,  Gary Jennings ,  Till Röhn

    Inventor： Martin Bachmann ,  Gary Jennings ,  Till Röhn

    IPC: A61K39/12 ,  C07K14/48 ,  A61P19/02 ,  A61P25/00

    CPC classification number: C07K16/22 ,  A61K2039/5258 ,  A61K2039/6075 ,  A61K2039/62 ,  C07K14/48 ,  C07K2317/73 ,  C12N7/00 ,  C12N2795/00023 ,  C12N2795/18123

    Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is NGF antigen. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of pain. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.

    Abstract translation: 本发明涉及医药，公共卫生，免疫学，分子生物学和病毒学领域。 本发明提供包含与至少一种抗原连接的病毒样颗粒（VLP）的组合物，其中所述抗原是NGF抗原。 本发明还提供了一种制备该组合物的方法。 本发明的组合物可用于疫苗的生产，特别是用于治疗疼痛。 此外，本发明的组合物诱导有效的免疫应答，特别是抗体应答。

    CAT Allergen Conjugates and Uses Thereof
    14.
    发明申请
    CAT Allergen Conjugates and Uses Thereof 审中-公开
    CAT过敏原共轭体及其用途

    公开(公告)号：US20110045013A1

    公开(公告)日：2011-02-24

    申请号：US12785174

    申请日：2010-05-21

    Applicant: Martin Bachmann ,  Monika Bauer ,  Klaus Dietmeier ,  Nicole Schmitz ,  Stephan Utzinger

    Inventor： Martin Bachmann ,  Monika Bauer ,  Klaus Dietmeier ,  Nicole Schmitz ,  Stephan Utzinger

    IPC: A61K39/35 ,  C12N7/00 ,  A61P37/08

    CPC classification number: C07K14/005 ,  A61K39/35 ,  A61K47/6901 ,  A61K2039/5258 ,  A61K2039/55505 ,  C07K2319/00

    Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.

    Abstract translation: 本发明涉及医药，公共卫生，免疫学，分子生物学和病毒学领域。 本发明提供包含病毒样颗粒（VLP）或病毒颗粒和至少一种抗原，特别是至少一种猫科动物抗原，更特别是至少一种作为人类变应原的猫科动物抗原的组合物。 在某些实施方案中，抗原是与VLP共价连接的Fel d1抗原或其片段。 本发明还提供了用于制备组合物的方法。 本发明的组合物在哺乳动物，特别是人类中诱导有效的免疫应答，特别是抗体应答。 本发明的组合物和方法可用于疫苗的制备，特别是用于治疗和/或预防猫皮屑和其它猫抗原和变应原的过敏。

    Selection of b cells with specificity if interest: method of preparation and use
    17.
    发明申请
    Selection of b cells with specificity if interest: method of preparation and use 审中-公开
    选择具有特异性的b细胞，如果兴趣：准备和使用方法

    公开(公告)号：US20070087331A1

    公开(公告)日：2007-04-19

    申请号：US10556904

    申请日：2004-05-14

    Applicant: Martin Bachmann ,  Dominique Gatto

    Inventor： Martin Bachmann ,  Dominique Gatto

    IPC: C12Q1/70 ,  C12N5/20 ,  G01N33/567

    CPC classification number: G01N33/56972 ,  G01N27/447 ,  G01N33/5052 ,  G01N33/54313 ,  G01N33/58

    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides methods using a composition comprising an ordered and repetitive antigen or antigenic determinant array for visualization and selection of B cells specific for the antigen. These B cells are useful for the production of monoclonal antibodies used for therapy, diagnostic or research purposes.

    Abstract translation: 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供使用包含有序和重复抗原或抗原决定簇的组合物的方法，用于可视化和选择对抗原特异性的B细胞。 这些B细胞可用于生产用于治疗，诊断或研究目的的单克隆抗体。

    Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
    18.
    发明申请
    Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b 审中-公开
    用于靶向亚型b的腺病毒细胞进入的修饰多肽

    公开(公告)号：US20070065408A1

    公开(公告)日：2007-03-22

    申请号：US10558279

    申请日：2004-05-27

    Applicant: Roger Beerli ,  Martin Bachmann

    Inventor： Roger Beerli ,  Martin Bachmann

    IPC: A61K48/00 ,  C07H21/04 ,  C12P21/06 ,  C07K16/30 ,  C07K14/705

    CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K16/46 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/43 ,  C12N15/62

    Abstract: This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct adenovirus infection specifically to cells having said cell surface molecule on their surface. The invention relates to nucleic acid sequences encoding fusion proteins comprising a) a polypeptide derived from the extracellular domain of CD46 and b) a heterologous polypeptide, methods for the production of the modified polypeptides and suitable recombinant expression vectors and host cells. Pharmaceutical compositions comprising the modified polypeptide of the invention are useful together with recombinant, genetically engineered adenovirus of subtype B for the treatment and prophylaxis of disorders and diseases, like cancer.

    Abstract translation: 本发明涉及包含两个功能组分的修饰的多肽：首先，衍生自CD46细胞外区域的多肽作为亚组B的腺病毒的特异性结合位点，其次是能够结合细胞表面分子的组分。 这种修饰的多肽能够将腺病毒感染特异性地引导到其表面上具有所述细胞表面分子的细胞。 本发明涉及编码融合蛋白的核酸序列，其包含a）源自CD46细胞外结构域的多肽和b）异源多肽，产生修饰多肽的方法和合适的重组表达载体和宿主细胞。 包含本发明修饰多肽的药物组合物与B型重组基因工程改造的腺病毒一起可用于治疗和预防疾病和疾病如癌症。

    Melan-a peptide analogue-virus-like-particle conjugates
    20.
    发明申请
    Melan-a peptide analogue-virus-like-particle conjugates 失效
    黑色素类似物 - 类似物 - 类似物 - 颗粒的共轭物

    公开(公告)号：US20060204475A1

    公开(公告)日：2006-09-14

    申请号：US10551054

    申请日：2004-03-25

    Applicant: Martin Bachmann ,  Vania Manolova ,  Edwin Meijerink ,  Karl Proba ,  Katrin Schwarz

    Inventor： Martin Bachmann ,  Vania Manolova ,  Edwin Meijerink ,  Karl Proba ,  Katrin Schwarz

    IPC: A61K48/00 ,  C12N15/86

    CPC classification number: A61K39/39 ,  A61K2039/5258 ,  A61K2039/55561 ,  A61K2039/6075 ,  A61K2039/62 ,  A61K2039/64 ,  C07K14/005 ,  C07K14/4748 ,  C12N2710/22022 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2760/10022 ,  Y02A50/467

    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpGVLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

    Abstract translation: 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸，以及衍生自与其连接的MelanA的特定肽。 这样的CpGVLP比其不含CpG的对应物显着地更具免疫原性，并且诱导增强的B和T细胞应答。 与VLP本身的免疫应答相似，对于任何偶联，融合或附着于VLP的MelanA肽类似物的免疫应答也相似地增强。 此外，针对MelanA肽类似物的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

Patent Agency Ranking